31
Supplemental table 1. All 222 HIV-1 p24 Gag overlapping peptides (OLPs
1 PIVQNLQGQM 41 SALSEGATPQ 81 DRLHPVHAGP 121 NPPIPVGEIY 161 FRDYVDRFYK 201 ILKALGPAAT 2 IVQNLQGQMV 42 ALSEGATPQD 82 RLHPVHAGPI 122 PPIPVGEIYK 162 RDYVDRFYKT 202 LKALGPAATL 3 VQNLQGQMVH 43 LSEGATPQDL 83 LHPVHAGPIA 123 PIPVGEIYKR 163 DYVDRFYKTL 203 KALGPAATLE 4 QNLQGQMVHQ 44 SEGATPQDLN 84 HPVHAGPIAP 124 IPVGEIYKRW 164 YVDRFYKTLR 204 ALGPAATLEE 5 NLQGQMVHQA 45 EGATPQDLNT 85 PVHAGPIAPG 125 PVGEIYKRWI 165 VDRFYKTLRA 205 LGPAATLEEM 6 LQGQMVHQAI 46 GATPQDLNTM 86 VHAGPIAPGQ 126 VGEIYKRWII 166 DRFYKTLRAE 206 GPAATLEEMM 7 QGQMVHQAIS 47 ATPQDLNTML 87 HAGPIAPGQM 127 GEIYKRWIIL 167 RFYKTLRAEQ 207 PAATLEEMMT 8 GQMVHQAISP 48 TPQDLNTMLN 88 AGPIAPGQMR 128 EIYKRWIILG 168 FYKTLRAEQA 208 AATLEEMMTA 9 QMVHQAISPR 49 PQDLNTMLNT 89 GPIAPGQMRE 129 IYKRWIILGL 169 YKTLRAEQAS 209 ATLEEMMTAC 10 MVHQAISPRT 50 QDLNTMLNTV 90 PIAPGQMREP 130 YKRWIILGLN 170 KTLRAEQASQ 210 TLEEMMTACQ 11 VHQAISPRTL 51 DLNTMLNTVG 91 IAPGQMREPR 131 KRWIILGLNK 171 TLRAEQASQE 211 LEEMMTACQG 12 HQAISPRTLN 52 LNTMLNTVGG 92 APGQMREPRG 132 RWIILGLNKI 172 LRAEQASQEV 212 EEMMTACQGV 13 QAISPRTLNA 53 NTMLNTVGGH 93 PGQMREPRGS 133 WIILGLNKIV 173 RAEQASQEVK 213 EMMTACQGVG 14 AISPRTLNAW 54 TMLNTVGGHQ 94 GQMREPRGSD 134 IILGLNKIVR 174 AEQASQEVKN 214 MMTACQGVGG 15 ISPRTLNAWV 55 MLNTVGGHQA 95 QMREPRGSDI 135 ILGLNKIVRM 175 EQASQEVKNW 215 MTACQGVGGP 16 SPRTLNAWVK 56 LNTVGGHQAA 96 MREPRGSDIA 136 LGLNKIVRMY 176 QASQEVKNWM 216 TACQGVGGPG 17 PRTLNAWVKV 57 NTVGGHQAAM 97 REPRGSDIAG 137 GLNKIVRMYS 177 ASQEVKNWMT 217 ACQGVGGPGH 18 RTLNAWVKVV 58 TVGGHQAAMQ 98 EPRGSDIAGT 138 LNKIVRMYSP 178 SQEVKNWMTE 218 CQGVGGPGHK 19 TLNAWVKVVE 59 VGGHQAAMQM 99 PRGSDIAGTT 139 NKIVRMYSPT 179 QEVKNWMTET 219 QGVGGPGHKA 20 LNAWVKVVEE 60 GGHQAAMQML 100 RGSDIAGTTS 140 KIVRMYSPTS 180 EVKNWMTETL 220 GVGGPGHKAR 21 NAWVKVVEEK 61 GHQAAMQMLK 101 GSDIAGTTST 141 IVRMYSPTSI 181 VKNWMTETLL 221 VGGPGHKARV 22 AWVKVVEEKA 62 HQAAMQMLKE 102 SDIAGTTSTL 142 VRMYSPTSIL 182 KNWMTETLLV 222 GGPGHKARVL 23 WVKVVEEKAF 63 QAAMQMLKET 103 DIAGTTSTLQ 143 RMYSPTSILD 183 NWMTETLLVQ
24 VKVVEEKAFS 64 AAMQMLKETI 104 IAGTTSTLQE 144 MYSPTSILDI 184 WMTETLLVQN 25 KVVEEKAFSP 65 AMQMLKETIN 105 AGTTSTLQEQ 145 YSPTSILDIR 185 MTETLLVQNA 26 VVEEKAFSPE 66 MQMLKETINE 106 GTTSTLQEQI 146 SPTSILDIRQ 186 TETLLVQNAN 27 VEEKAFSPEV 67 QMLKETINEE 107 TTSTLQEQIG 147 PTSILDIRQG 187 ETLLVQNANP 28 EEKAFSPEVI 68 MLKETINEEA 108 TSTLQEQIGW 148 TSILDIRQGP 188 TLLVQNANPD 29 EKAFSPEVIP 69 LKETINEEAA 109 STLQEQIGWM 149 SILDIRQGPK 189 LLVQNANPDC 30 KAFSPEVIPM 70 KETINEEAAE 110 TLQEQIGWMT 150 ILDIRQGPKE 190 LVQNANPDCK 31 AFSPEVIPMF 71 ETINEEAAEW 111 LQEQIGWMTN 151 LDIRQGPKEP 191 VQNANPDCKT 32 FSPEVIPMFS 72 TINEEAAEWD 112 QEQIGWMTNN 152 DIRQGPKEPF 192 QNANPDCKTI 33 SPEVIPMFSA 73 INEEAAEWDR 113 EQIGWMTNNP 153 IRQGPKEPFR 193 NANPDCKTIL 34 PEVIPMFSAL 74 NEEAAEWDRL 114 QIGWMTNNPP 154 RQGPKEPFRD 194 ANPDCKTILK 35 EVIPMFSALS 75 EEAAEWDRLH 115 IGWMTNNPPI 155 QGPKEPFRDY 195 NPDCKTILKA 36 VIPMFSALSE 76 EAAEWDRLHP 116 GWMTNNPPIP 156 GPKEPFRDYV 196 PDCKTILKAL 37 IPMFSALSEG 77 AAEWDRLHPV 117 WMTNNPPIPV 157 PKEPFRDYVD 197 DCKTILKALG 38 PMFSALSEGA 78 AEWDRLHPVH 118 MTNNPPIPVG 158 KEPFRDYVDR 198 CKTILKALGP 39 MFSALSEGAT 79 EWDRLHPVHA 119 TNNPPIPVGE 159 EPFRDYVDRF 199 KTILKALGPA 40 FSALSEGATP 80 WDRLHPVHAG 120 NNPPIPVGEI 160 PFRDYVDRFY 200 TILKALGPAA
32
Supplemental figure 1. HLA-C*03:04 stabilization on 221-ICP47-C*03:04 cells pulsed with no peptide, GKL, GAL, and OLP11. Representative histograms of HLA-C stabilization on 221-ICP47- C*03:04 cells in the presence of no peptide (solid grey), control peptide GKL (GAVDPLLKL, dotted line), control peptide GAL (GAVDPLLAL, dashed line) and OLP11 (HQAISPRTL, continuous line).
Supplemental figure 2. HLA-C*03:04 stabilization on 221-ICP47-C*03:04 cells pulsed with
variants of OLP30, OLP34, and OLP163. 221-ICP47-C*03:04 cells were stained with a pan-HLA
antibody (W6/32-APC) after peptide pre-incubation as indicated. Variant epitopes of OLP30,
OLP34, and OLP163 did not significantly differ from their consensus sequence counterpart in
their ability to stabilize HLA-C*03:04.
No pep&de GAL GKL OLP11
% o f Ma x
Pan HLA (W6/32) staining
(-) GAL GKL Cseq I Cseq A M T Cseq A C I V 0
2 4 6 8 10
